Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2021 Filed May 12, 2021 23:47 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 510 | $541.01 | $275,915.10 |
DisclosureSEC source: 0001567619-21-009749 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,703 Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:01 UTC |
JUNIUS DANIEL MDirector
|
GrantCommon Stock | 11 | $548.99 | $6,038.89 |
DisclosureSEC source: 0001567619-21-009017 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,886 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,250.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:01 UTC |
ESSIG STUARTDirector
|
GrantCommon Stock | 36 | $548.99 | $19,763.64 |
DisclosureSEC source: 0001567619-21-009016 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:00 UTC |
COLLINS AshaDirector
|
GrantCommon Stock | 36 | $548.99 | $19,763.64 |
DisclosureSEC source: 0001567619-21-009015 · doc1.xml · nonDerivative · entry 1 COLLINS Asha · CIK 0001832272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 22:06 UTC |
TWIGGE GIOVANISenior Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 3,227 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-005197 · doc1.xml · derivative · entry 2 TWIGGE GIOVANI · CIK 0001500399 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,227 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 22,028 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 22:06 UTC |
TWIGGE GIOVANISenior Vice President
|
Exercise / conversionCommon Stock | 3,227 | $67.85 | $218,951.95 |
DisclosureSEC source: 0001567619-21-005197 · doc1.xml · nonDerivative · entry 1 TWIGGE GIOVANI · CIK 0001500399 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:05 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,476 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-005196 · doc1.xml · derivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,476 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2021. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:05 UTC |
POLEWACZYK JAMES FExecutive Vice President
|
Exercise / conversionCommon Stock | 1,476 | $67.85 | $100,146.60 |
DisclosureSEC source: 0001567619-21-005196 · doc1.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 00:35 UTC |
HENDERSON REBECCA MDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001567619-21-004966 · doc1.xml · derivative · entry 3 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable on May 3, 2018. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 00:35 UTC |
HENDERSON REBECCA MDirector
|
SaleCommon Stock | 3,046 | $513.41 | $1,563,839.55 |
DisclosureSEC source: 0001567619-21-004966 · doc1.xml · nonDerivative · entry 2 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,696 Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 00:35 UTC |
HENDERSON REBECCA MDirector
|
Exercise / conversionCommon Stock | 3,046 | $160.28 | $488,212.88 |
DisclosureSEC source: 0001567619-21-004966 · doc1.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 00:34 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,476 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004965 · doc1.xml · derivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,476 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2021. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 00:34 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionCommon Stock | 1,476 | $67.85 | $100,146.60 |
DisclosureSEC source: 0001567619-21-004965 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:01 UTC |
Underberg Sharon E.SVP, Gen. Counsel & Secretary
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 483 | Not disclosed Strike: $206.94 | Not disclosed |
DisclosureSEC source: 0001567619-21-004796 · doc1.xml · derivative · entry 2 Underberg Sharon E. · CIK 0001630353 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,449 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2020. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:01 UTC |
Underberg Sharon E.SVP, Gen. Counsel & Secretary
|
Exercise / conversionCommon Stock | 483 | $206.94 | $99,952.02 |
DisclosureSEC source: 0001567619-21-004796 · doc1.xml · nonDerivative · entry 1 Underberg Sharon E. · CIK 0001630353 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:00 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,000 | Not disclosed Strike: $85.00 | Not disclosed |
DisclosureSEC source: 0001567619-21-004793 · doc1.xml · derivative · entry 6 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,902 Underlying: Common Stock · 1,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the date of the 2017 annual meeting of shareholders. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:00 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 898 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-21-004793 · doc1.xml · derivative · entry 5 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 898 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 449 shares on May 6, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:00 UTC |
JUNIUS DANIEL MDirector
|
SaleCommon Stock | 1,888 | $538.57 | $1,016,815.06 |
DisclosureSEC source: 0001567619-21-004793 · doc1.xml · nonDerivative · entry 4 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,875 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:00 UTC |
JUNIUS DANIEL MDirector
|
SaleCommon Stock | 10 | $539.19 | $5,391.90 |
DisclosureSEC source: 0001567619-21-004793 · doc1.xml · nonDerivative · entry 3 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,763 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:00 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionCommon Stock | 1,000 | $85.00 | $85,000.00 |
DisclosureSEC source: 0001567619-21-004793 · doc1.xml · nonDerivative · entry 2 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:00 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionCommon Stock | 898 | $79.54 | $71,426.92 |
DisclosureSEC source: 0001567619-21-004793 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:01 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,475 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004794 · doc1.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,475 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2021. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:01 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
Exercise / conversionCommon Stock | 1,475 | $67.85 | $100,078.75 |
DisclosureSEC source: 0001567619-21-004794 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:01 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,474 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004515 · doc1.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,474 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 4,395 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on February 14, 2021. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:01 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 1,474 | $67.85 | $100,010.90 |
DisclosureSEC source: 0001567619-21-004515 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:00 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,000 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-21-004615 · doc1.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,632 Underlying: Common Stock · 1,000 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 1,000 | $555.56 | $555,561.30 |
DisclosureSEC source: 0001567619-21-004615 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,737 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:00 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionCommon Stock | 1,000 | $79.54 | $79,540.00 |
DisclosureSEC source: 0001567619-21-004615 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 25,000 | Not disclosed Strike: $52.00 | Not disclosed |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · derivative · entry 9 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,002 Underlying: Common Stock · 25,000 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 24,501 shares of Issuer common stock that became exercisable in five annual installments beginning December 5, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
SaleCommon Stock | 100 | $543.14 | $54,314.00 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 8 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,222 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
SaleCommon Stock | 583 | $542.08 | $316,033.46 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,322 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $542.08 to a high of $542.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
SaleCommon Stock | 300 | $540.82 | $162,246.78 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,905 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $540.218 to a high of $541.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
SaleCommon Stock | 500 | $538.83 | $269,415.00 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,205 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
SaleCommon Stock | 3,069 | $537.84 | $1,650,628.81 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,705 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $537.388 to a high of $538.12 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
SaleCommon Stock | 5,376 | $536.78 | $2,885,730.89 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,744 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $536.33 to a high of $537.31 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
SaleCommon Stock | 3,940 | $535.94 | $2,111,600.05 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,150 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $535.325 to a high of $536.28 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC |
MAZELSKY JONATHAN JAYDirector · President & CEO
|
Exercise / conversionCommon Stock | 25,000 | $52.00 | $1,300,000.00 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 00:33 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
SaleCommon Stock | 1,307 | $539.58 | $705,231.06 |
DisclosureSEC source: 0001567619-21-004326 · doc1.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,714 Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 00:31 UTC |
Lane MichaelExecutive Vice President
|
SaleCommon Stock | 850 | $545.00 | $463,250.00 |
DisclosureSEC source: 0001567619-21-004324 · doc1.xml · nonDerivative · entry 7 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,624 Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:26 UTC |
Claflin Bruce L.Director
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,125 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001567619-21-004471 · doc1.xml · derivative · entry 6 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,921 Underlying: Common Stock · 1,125 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on May 3, 2018. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:26 UTC |
Claflin Bruce L.Director
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,902 | Not disclosed Strike: $85.00 | Not disclosed |
DisclosureSEC source: 0001567619-21-004471 · doc1.xml · derivative · entry 5 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,902 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the date of the 2017 annual meeting of shareholders. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:26 UTC |
Claflin Bruce L.Director
|
SaleCommon Stock | 586 | $537.19 | $314,795.16 |
DisclosureSEC source: 0001567619-21-004471 · doc1.xml · nonDerivative · entry 4 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $537.15 to a high of $537.23 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:26 UTC |
Claflin Bruce L.Director
|
SaleCommon Stock | 6,745 | $536.89 | $3,621,293.37 |
DisclosureSEC source: 0001567619-21-004471 · doc1.xml · nonDerivative · entry 3 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $536.13 to a high of $537.125 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:26 UTC |
Claflin Bruce L.Director
|
Exercise / conversionCommon Stock | 1,125 | $160.28 | $180,315.00 |
DisclosureSEC source: 0001567619-21-004471 · doc1.xml · nonDerivative · entry 2 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:26 UTC |
Claflin Bruce L.Director
|
Exercise / conversionCommon Stock | 5,902 | $85.00 | $501,670.00 |
DisclosureSEC source: 0001567619-21-004471 · doc1.xml · nonDerivative · entry 1 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:35 UTC |
Underberg Sharon E.SVP, Gen. Counsel & Secretary
|
Exercise / conversionRestricted Stock Unit · Derivative | 217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004330 · doc1.xml · derivative · entry 8 Underberg Sharon E. · CIK 0001630353 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,649 Underlying: Common Stock · 217 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F8 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:35 UTC |
Underberg Sharon E.SVP, Gen. Counsel & Secretary
|
Exercise / conversionRestricted Stock Unit · Derivative | 453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004330 · doc1.xml · derivative · entry 7 Underberg Sharon E. · CIK 0001630353 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,866 Underlying: Common Stock · 453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F8 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:35 UTC |
Underberg Sharon E.SVP, Gen. Counsel & Secretary
|
GrantRestricted Stock Unit · Derivative | 551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004330 · doc1.xml · derivative · entry 6 Underberg Sharon E. · CIK 0001630353 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,349 Underlying: Common Stock · 551 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F8 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:35 UTC |
Underberg Sharon E.SVP, Gen. Counsel & Secretary
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 183 | Not disclosed Strike: $544.08 | Not disclosed |
DisclosureSEC source: 0001567619-21-004330 · doc1.xml · derivative · entry 5 Underberg Sharon E. · CIK 0001630353 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183 Underlying: Common Stock · 183 shares Expires 2031-02-13 F2 · derivative.exercise_price: Closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021. F8 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:35 UTC |
Underberg Sharon E.SVP, Gen. Counsel & Secretary
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 5,119 | Not disclosed Strike: $544.08 | Not disclosed |
DisclosureSEC source: 0001567619-21-004330 · doc1.xml · derivative · entry 4 Underberg Sharon E. · CIK 0001630353 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,119 Underlying: Common Stock · 5,119 shares Expires 2031-02-13 F2 · derivative.exercise_price: Closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021. F8 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.